{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:57Z","timestamp":1789689657320,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Transcatheter aortic valve implantation (TAVI) has become standard treatment for elderly patients with symptomatic severe aortic valve stenosis. The ACURATE neo AS study evaluates 30-day and 1-year clinical and hemodynamic outcomes in patients treated with the ACURATE <jats:italic>neo<\/jats:italic>2 valve.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The primary endpoint of this single-arm multicenter study is 30-day all-cause mortality. Other key endpoints include device performance, echocardiographic measures assessed by an independent core laboratory, and VARC-2 clinical efficacy and safety endpoints through 12\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study enrolled 120 patients (mean age 82.1\u2009\u00b1\u20094.0\u00a0years; 67.5% female, mean baseline STS score 4.8\u2009\u00b1\u20093.8%). The VARC-2 composite safety endpoint at 30\u00a0days occurred in 13.3% of patients. All-cause mortality was 3.3% at 30\u00a0days and 11.9% at 1\u00a0year. The 30-day stroke rate was 2.5% (disabling stroke 1.7%); there were no new strokes between 30\u00a0days and 12\u00a0months. The rate of permanent pacemaker implantation was 15.0% (18\/120) at 30\u00a0days and 17.8% (21\/120) at 1\u00a0year. No patients required re-intervention for valve-related dysfunction and there were no cases of valve thrombosis or endocarditis. Patients demonstrated significant improvement in mean aortic valve gradient (baseline 38.9\u2009\u00b1\u200913.1\u00a0mmHg, 1\u00a0year 7.8\u2009\u00b1\u20093.5\u00a0mmHg; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 in a paired analysis). In the overall population, paravalvular leak was evaluated at 1\u00a0year as none\/trace in 60.5%, mild in 37.0%, and moderate in 2.5%; no patients had severe PVL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>One-year outcomes from the ACURATE neo AS study support the safety and performance of TAVI with the ACURATE <jats:italic>neo<\/jats:italic>2 valve.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00392-021-01882-3","type":"journal-article","created":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T06:02:29Z","timestamp":1624168949000},"page":"1912-1920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["The ACURATE neo2 valve system for transcatheter aortic valve implantation: 30-day and 1-year outcomes"],"prefix":"10.1007","volume":"110","author":[{"given":"Helge","family":"M\u00f6llmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Holzhey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hilker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Toggweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Treede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Joner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"S\u00f8ndergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Christen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Allocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Keun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,20]]},"reference":[{"key":"1882_CR1","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","volume":"370","author":"DH Adams","year":"2014","unstructured":"Adams DH, Popma JJ, Reardon MJ et al (2014) Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370:1790\u20131798. https:\/\/doi.org\/10.1056\/NEJMoa1400590","journal-title":"N Engl J Med"},{"key":"1882_CR2","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","volume":"364","author":"CR Smith","year":"2011","unstructured":"Smith CR, Leon MB, Mack MJ et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364:2187\u20132198. https:\/\/doi.org\/10.1056\/NEJMoa1103510","journal-title":"N Engl J Med"},{"key":"1882_CR3","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/S0140-6736(15)60308-7","volume":"385","author":"MJ Mack","year":"2015","unstructured":"Mack MJ, Leon MB, Smith CR et al (2015) 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. The Lancet 385:2477\u20132484. https:\/\/doi.org\/10.1016\/S0140-6736(15)60308-7","journal-title":"The Lancet"},{"key":"1882_CR4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","volume":"374","author":"MB Leon","year":"2016","unstructured":"Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374:1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1514616","journal-title":"N Engl J Med"},{"key":"1882_CR5","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/eurheartj\/ehs003","volume":"33","author":"SJ Head","year":"2012","unstructured":"Head SJ, Mokhles MM, Osnabrugge RLJ et al (2012) The impact of prosthesis\u2013patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. Eur Heart J 33:1518\u20131529. https:\/\/doi.org\/10.1093\/eurheartj\/ehs003","journal-title":"Eur Heart J"},{"key":"1882_CR6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2014.06.1195","volume":"64","author":"P Pibarot","year":"2014","unstructured":"Pibarot P, Weissman N, Stewart W et al (2014) Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER Trial Cohort A analysis. J Am Coll Cardiol 64:1323\u20131334. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1195","journal-title":"J Am Coll Cardiol"},{"key":"1882_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jcin.2018.10.053","volume":"12","author":"TH J\u00f8rgensen","year":"2019","unstructured":"J\u00f8rgensen TH, Backer OD, Gerds TA et al (2019) Mortality and heart failure hospitalization in patients with conduction abnormalities after transcatheter aortic valve replacement. JACC Cardiovasc Interv 12:52\u201361. https:\/\/doi.org\/10.1016\/j.jcin.2018.10.053","journal-title":"JACC Cardiovasc Interv"},{"key":"1882_CR8","doi-asserted-by":"publisher","unstructured":"Faroux L, Chen S, Muntan\u00e9-Carol G, et al (2020) Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis. Eur Heart J 41:2771\u20132781. https:\/\/doi.org\/10.1093\/eurheartj\/ehz924","DOI":"10.1093\/eurheartj\/ehz924"},{"key":"1882_CR9","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.4244\/eijv9ssa22","volume":"9","author":"H M\u00f6llmann","year":"2013","unstructured":"M\u00f6llmann H, Diemert P, Grube E et al (2013) Symetis ACURATE TFTM aortic bioprosthesis. EuroIntervention 9:S107\u2013S110. https:\/\/doi.org\/10.4244\/eijv9ssa22","journal-title":"EuroIntervention"},{"key":"1882_CR10","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcin.2018.03.023","volume":"11","author":"W-K Kim","year":"2018","unstructured":"Kim W-K, Hengstenberg C, Hilker M et al (2018) The SAVI-TF registry: 1-year outcomes of the European post-market registry using the ACURATE neo transcatheter heart valve under real-world conditions in 1,000 patients. JACC Cardiovasc Interv 11:1368\u20131374. https:\/\/doi.org\/10.1016\/j.jcin.2018.03.023","journal-title":"JACC Cardiovasc Interv"},{"key":"1882_CR11","doi-asserted-by":"publisher","first-page":"e1764","DOI":"10.4244\/EIJ-D-17-00628","volume":"13","author":"H M\u00f6llmann","year":"2018","unstructured":"M\u00f6llmann H, Hengstenberg C, Hilker M et al (2018) Real-world experience using the ACURATE neoTM prosthesis: 30-day outcomes of 1000 patients enrolled in the SAVI-TF registry. EuroIntervention 13:e1764\u2013e1770. https:\/\/doi.org\/10.4244\/EIJ-D-17-00628","journal-title":"EuroIntervention"},{"key":"1882_CR12","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/S0140-6736(19)32220-2","volume":"394","author":"J Lanz","year":"2019","unstructured":"Lanz J, Kim W-K, Walther T et al (2019) Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. The Lancet 394:1619\u20131628. https:\/\/doi.org\/10.1016\/S0140-6736(19)32220-2","journal-title":"The Lancet"},{"key":"1882_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051547","author":"C Tamburino","year":"2020","unstructured":"Tamburino C, Bleiziffer S, Thiele H et al (2020) Comparison of self-expanding bioprostheses for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: the SCOPE 2 randomized clinical trial. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051547","journal-title":"Circulation"},{"key":"1882_CR14","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","volume":"60","author":"AP Kappetein","year":"2012","unstructured":"Kappetein AP, Head SJ, Genereux P et al (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document. J Am Coll Cardiol 60:1438\u20131454. https:\/\/doi.org\/10.1016\/j.jacc.2012.09.001","journal-title":"J Am Coll Cardiol"},{"key":"1882_CR15","doi-asserted-by":"publisher","unstructured":"Genereux P (2021) Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol 77:2717\u20132746. https:\/\/doi.org\/10.1016\/j.jacc.2021.02.038","DOI":"10.1016\/j.jacc.2021.02.038"},{"key":"1882_CR16","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2018.09.014","volume":"72","author":"L S\u00f8ndergaard","year":"2018","unstructured":"S\u00f8ndergaard L, Rod\u00e9s-Cabau J, Hans-Peter Linke A et al (2018) Transcatheter aortic valve replacement with a repositionable self-expanding prosthesis: the PORTICO-I trial 1-year outcomes. J Am Coll Cardiol 72:2859\u20132867. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.014","journal-title":"J Am Coll Cardiol"},{"key":"1882_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jcin.2018.11.036","volume":"12","author":"M Pagnesi","year":"2019","unstructured":"Pagnesi M, Kim W-K, Conradi L et al (2019) Transcatheter aortic valve replacement with next-generation self-expanding devices: a multicenter, retrospective, propensity-matched comparison of Evolut PRO versus accurate neo transcatheter heart valves. JACC Cardiovasc Interv 12:433\u2013443. https:\/\/doi.org\/10.1016\/j.jcin.2018.11.036","journal-title":"JACC Cardiovasc Interv"},{"key":"1882_CR18","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.jcin.2017.06.026","volume":"10","author":"O Husser","year":"2017","unstructured":"Husser O, Kim W-K, Pellegrini C et al (2017) Multicenter comparison of novel self-expanding versus balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv 10:2078\u20132087. https:\/\/doi.org\/10.1016\/j.jcin.2017.06.026","journal-title":"JACC Cardiovasc Interv"},{"key":"1882_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/ccd.28144","volume":"94","author":"C Pellegrini","year":"2019","unstructured":"Pellegrini C, Rheude T, Trenkwalder T et al (2019) One-year clinical outcome with a novel self-expanding transcatheter heart valve. Catheter Cardiovasc Interv 94:783\u2013792. https:\/\/doi.org\/10.1002\/ccd.28144","journal-title":"Catheter Cardiovasc Interv"},{"key":"1882_CR20","doi-asserted-by":"publisher","first-page":"e005013","DOI":"10.1161\/CIRCINTERVENTIONS.117.005013","volume":"10","author":"V Mauri","year":"2017","unstructured":"Mauri V, Kim WK, Abumayyaleh M et al (2017) Short-term outcome and hemodynamic performance of next-generation self-expanding versus balloon-expandable transcatheter aortic valves in patients with small aortic annulus: a multicenter propensity-matched comparison. Circ Cardiovasc Interv 10:e005013. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.117.005013","journal-title":"Circ Cardiovasc Interv"},{"key":"1882_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1161\/circulationaha.110.946533","volume":"123","author":"C Tamburino","year":"2011","unstructured":"Tamburino C, Capodanno D, Ramondo A et al (2011) Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 123:299\u2013308. https:\/\/doi.org\/10.1161\/circulationaha.110.946533","journal-title":"Circulation"},{"key":"1882_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1161\/circulationaha.113.002677","volume":"129","author":"E Van Belle","year":"2014","unstructured":"Van Belle E, Juthier F, Susen S et al (2014) Postprocedural aortic regurgitation in balloon-expandable and self-expandable transcatheter aortic valve replacement procedures: analysis of predictors and impact on long-term mortality: insights from the FRANCE2 Registry. Circulation 129:1415\u20131427. https:\/\/doi.org\/10.1161\/circulationaha.113.002677","journal-title":"Circulation"},{"key":"1882_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/hrt.2010.217158","volume":"97","author":"M Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab M, Zahn R, Horack M et al (2011) Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German Transcatheter Aortic Valve Interventions registry. Heart 97:899\u2013906. https:\/\/doi.org\/10.1136\/hrt.2010.217158","journal-title":"Heart"},{"key":"1882_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.05.044","author":"W-K Kim","year":"2020","unstructured":"Kim W-K, M\u00f6llmann H, Liebetrau C et al (2020) Effectiveness and safety of the ACURATE neo prosthesis in 1,000 patients with aortic stenosis. Am J Cardiol. https:\/\/doi.org\/10.1016\/j.amjcard.2020.05.044","journal-title":"Am J Cardiol"},{"key":"1882_CR25","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","volume":"380","author":"JJ Popma","year":"2019","unstructured":"Popma JJ, Deeb GM, Yakubov SJ et al (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380:1706\u20131715. https:\/\/doi.org\/10.1056\/NEJMoa1816885","journal-title":"N Engl J Med"},{"key":"1882_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1540-8167.2011.02211.x","volume":"23","author":"D Erkapic","year":"2012","unstructured":"Erkapic D, De Rosa S, Kelava A et al (2012) Risk for permanent pacemaker after transcatheter aortic valve implantation: a comprehensive analysis of the literature. J Cardiovasc Electrophysiol 23:391\u2013397. https:\/\/doi.org\/10.1111\/j.1540-8167.2011.02211.x","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01882-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01882-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01882-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T12:06:03Z","timestamp":1638446763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01882-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,20]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1882"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01882-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,20]]},"assertion":[{"value":"11 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.M. reports receipt of honoraria or consultation fees from Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, St. Jude Medical. D.H. is a proctor for Boston Scientific. M.H. reports receipt of honoraria or consultation fees from Boston Scientific and New Valve Technology. S.T. is a consultant and proctor for Boston Scientific, Abbott Vascular and New Valve Technology \/Biosensors, has received speaker honoraria from Medtronic, institutional research grants from Boston Scientific and Fumedica, and is a board member of and holds equity in Hi-D Imaging. U.S. reports receipt of honoraria or consultation fees from Abbott, Biotronik, Boston Scientific, Edwards Lifesciences and Medtronic. H.T. reports receipt of honoraria or consultation fees from Medtronic, Biotronik, Boston Scientific, TriCares, JenaValve. M.J. did not report any conflicts of interest. L.S. has received consultant fees and institutional research grants from Boston Scientific. T.C. and D.A. are employees of and shareholders in Boston Scientific. W.K. reports receipt of honoraria or consultation fees from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}